-
A BAYESIAN FRAMEWORK FOR NETWORK META-ANALYSIS OF INDIVIDUAL PATIENT DATA SURVIVAL OUTCOMES USING FLEXIBLE PARAMETRIC SURVIVAL MODELS
Aug 11, 2026, 17:16 PM -
TEST, TARGET, TREAT: COST-EFFECTIVENESS OF HSCRP-GUIDED TREATMENT IN PEOPLE WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE IN SWEDEN
Aug 11, 2026, 17:16 PM -
PROJECTED HEALTH OUTCOMES AND RESOURCE USE: IMPACT OF INTRODUCING PEMBROLIZUMAB (INCLUDING INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION) IN EARLY-STAGE HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN THE U.S. MEDICARE POPULATION
Aug 11, 2026, 17:16 PM -
PATIENT INVOLVEMENT IN HTA ACROSS THE EU4 AND UK: A MAPPING OF ACCESS POINTS AND INFLUENCE ACROSS HTA MILESTONES
Aug 11, 2026, 17:16 PM -
IMPACT OF ESTIMAND MISALIGNMENT IN INDIRECT TREATMENT COMPARISONS OF ONCOLOGY TRIALS WITH TREATMENT SWITCHING - A SIMULATION STUDY
Aug 11, 2026, 17:16 PM -
A REAL-WORLD, GLOBAL SURVEY OF THE DISEASE BURDEN OF TREATED HEMOPHILIA B MALE PATIENTS
Aug 11, 2026, 17:16 PM -
MAPPING FOUNDATIONAL DECISION-AI METHODS IN HEALTH ECONOMIC EVALUATION: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
BEYOND COSTS: REAL WORLD EVIDENCE ON THE SOCIETAL AND UNDERRECOGNIZED SOCIAL BURDEN OF RHEUMATOID ARTHRITIS IN MOROCCO
Aug 11, 2026, 17:16 PM -
STIMULATING CAPACITY BUILDING AT EUROPEAN HTA BODIES: EARLY EXPERIENCE FROM THE SUSTAIN-HTA FELLOWSHIP PROGRAM
Aug 11, 2026, 17:16 PM -
BEYOND THE AGGREGATE RATE: HOW GERMANY'S FORSCHUNGSDATENZENTRUM GESUNDHEIT (FDZ) WILL RESHAPE VACCINATION COVERAGE MONITORING
Aug 11, 2026, 17:16 PM -
SOCIAL RETURN ON INVESTMENT METHODOLOGY FOR PEDIATRIC PRESYMPTOMATIC TYPE 1 DIABETES (T1D) SCREENING IN SPAIN: A MULTI-STAKEHOLDER FRAMEWORK
Aug 11, 2026, 17:16 PM -
POSITIONING IL-23 AND JAK INHIBITORS IN TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE CROHN'S DISEASE: A COST-UTILITY ANALYSIS FROM HONG KONG
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF ACUTE MYOCARDIAL INFARCTION (AMI) IN JAPAN AND THE ROLE OF CARDIOVASCULAR INFLAMMATION
Aug 11, 2026, 17:16 PM -
AGE, COMORBIDITY, AND TIME TO TREATMENT AS DRIVERS OF FIRST-LINE BTKI UTILIZATION IN REAL-WORLD CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A NORSTELLALINQ ANALYSIS
Aug 11, 2026, 17:16 PM -
A SIMPLIFIED TREATMENT-SEQUENCE MODELING APPROACH FOR EARLY ONCOLOGY DECISION SUPPORT USING LIMITED SURVIVAL DATA: A CASE STUDY IN FAVORABLE-RISK ADVANCED RENAL CELL CARCINOMA
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF ADD-ON CANNABIDIOL FOR THE TREATMENT OF THERAPY-RESISTANT SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN SWEDEN
Aug 11, 2026, 17:16 PM -
CHARACTERIZING PARTICIPANTS IN THE ONTARIO HIV TREATMENT NETWORK COHORT STUDY (OCS): A COMPARISON AMONG 14 SITES
Aug 11, 2026, 17:16 PM -
TRENDS IN UTILITY VALUES APPLIED IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)
Aug 11, 2026, 17:16 PM -
COMPARATIVE EFFECTIVENESS OF ODEVIXIBAT VERSUS MARALIXIBAT IN ALAGILLE SYNDROME: A MODELING-BASED ANALYSIS OF PRURITUS RESPONSE, DURABILITY, AND LONG-TERM PATIENT-RELEVANT OUTCOMES
Aug 11, 2026, 17:16 PM -
DISTRIBUTION OF PHARMACEUTICALS REIMBURSED AT A 100% RATE BY ANATOMICAL THERAPEUTIC CHEMICAL (ATC) GROUP IN ESTONIA, 2023-2026: AN ANALYSIS USING ESTONIAN HEALTH INSURANCE FUND (EHIF) DATA
Aug 11, 2026, 17:16 PM
